Operating Margin: Operating margin measurement of what proportion of a company's revenue is left over after paying for variable costs of production such as wages, raw materials, etc. Calculated as: Operating Income / Total Revenues
Crescent Biopharma, Inc. (CBIO) had Operating Margin of -2380.08% for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$1.04M |
|
$-23.28M |
|
-- |
|
$1.04M |
|
$25.77M |
|
$-24.73M |
|
$1.45M |
|
$-23.28M |
|
$-23.28M |
|
$-23.28M |
|
$-23.28M |
|
$-23.28M |
|
$-23.28M |
|
$-24.73M |
|
$-24.66M |
|
30.40M |
|
30.40M |
|
$-0.70 |
|
$-0.70 |
|
| Balance Sheet Financials | |
$195.56M |
|
$0.93M |
|
$3.57M |
|
$199.13M |
|
$14.19M |
|
-- |
|
$1.09M |
|
$15.28M |
|
$179.85M |
|
$183.85M |
|
$183.85M |
|
27.57M |
|
| Cash Flow Statement Financials | |
$-8.94M |
|
$-8.15M |
|
$-6.95M |
|
$213.30M |
|
$189.27M |
|
$-24.03M |
|
$4.11M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
13.78 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
|
Operating Margin |
-2380.08% |
-2380.08% |
|
-- |
|
-2240.91% |
|
-2240.91% |
|
$-9.08M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-12.95% |
|
-12.66% |
|
-11.69% |
|
-12.66% |
|
$6.67 |
|
$-0.30 |
|
$-0.29 |
|